Histologic Findings and Tissue B-Cell Depletion in Endoscopic Mucosal Biopsy Specimens of the Gastrointestinal Tract After Treatment With Rituximab.
Am J Clin Pathol
; 157(3): 353-364, 2022 Mar 03.
Article
em En
| MEDLINE
| ID: mdl-34520518
ABSTRACT
OBJECTIVES:
Rituximab (RTX) is associated with variable adverse gastrointestinal (GI) events. However, the histologic correlate in affected patients is not well defined.METHODS:
Patients (nâ =â 93) who had received RTX and undergone endoscopic biopsies were identified. CD20 and PAX5 immunostains were performed on biopsy specimens showing inflammatory pathology (group A, 36 patients) and 35 of 57 noninflammatory biopsies (group B) that were taken within 1 year from the last RTX infusion. Histologic findings were correlated with tissue B-cell depletion (CD20/PAX5-/-).RESULTS:
B cells were depleted in 12 (33%) of 36 group A biopsy specimens. After excluding biopsies taken more than 1 year from the last RTX infusion, the frequencies of tissue B-cell depletion were similar between group A (12/26; 46.2%) and group B (17/35; 48.6%) (Pâ >â .05). Also, the frequencies of inflammatory pathology were not statistically different whether B cells were depleted or not (Pâ >â .05). In group A with tissue B-cell depletion (nâ =â 12), causality was indicated in two (17%) cases showing lymphocytic colitis pattern of injury (LCPI).CONCLUSIONS:
In RTX-treated patients, tissue B-cell depletion does not appear to be the main cause of inflammatory pathology in the GI tract. A minor subset, however, develops histologic evidence of potential RTX-induced effect, notably in the form of LCPI.Palavras-chave
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Linfócitos B
/
Antígenos CD20
Tipo de estudo:
Diagnostic_studies
/
Prognostic_studies
Limite:
Humans
Idioma:
En
Revista:
Am J Clin Pathol
Ano de publicação:
2022
Tipo de documento:
Article